AI in Clinical Trials: The Shift From Experimentation to Adoption

Clinical trials are at an inflection point driven by AI innovation, regulatory change, and growing pressure to move faster and smarter. Powerful AI tools are everywhere, but impact only happens when they’re adopted at scale.

In this interview, Ariel Katz, Co-founder and CEO of H1, sits down with Rebecca Willumson, Publisher at Fierce BioTech, for a conversation on how artificial intelligence is reshaping drug development. See what it takes to become truly AI-ready across R&D, medical, and commercial teams, and why decisive action now will separate industry leaders from those left behind.

Watch the full interview below:

Read the Fierce Biotech article: How AI is reshaping clinical trials and market access.